Australia - English - Department of Health (Therapeutic Goods Administration)

devatis pty ltd - amoxicillin trihydrate, quantity: 91.823 mg/ml; potassium clavulanate, quantity: 13.58 mg/ml - suspension, powder for - excipient ingredients: saccharin sodium; xanthan gum; methyl hydroxybenzoate; succinic acid; colloidal anhydrous silica; silicon dioxide; hypromellose; flavour - deva-amoxyclav 400/57 (amoxicillin and clavulanic acid) oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology):,skin and skin structure infections,urinary tract infections (complicated and uncomplicated),upper respiratory tract infections including sinusitis and otitis media,lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to deva-amoxyclav 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to deva-amoxyclav 400/57, should not require the addition of another antibiotic due to the amoxicillin content of deva-amoxyclav 400/57.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - doxycycline hyclate, quantity: 116.3 mg (equivalent: doxycycline, qty 100 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; purified water; hypromellose phthalate; povidone; diethyl phthalate; magnesium stearate; wheat starch; hypromellose; lactose monohydrate; hyprolose; gelatin; ethanol; shellac; pharmaceutical glaze; carbon black - doxycycline is primarily bacteriostatic and is thought to exert its antimicrobial effect by the inhibition of protein synthesis. doxycycline is active against a wide range of gram-positive and gram-negative organisms. note: the 50 mg capsule is not a paediatric formulation. mayne pharma doxycycline capsules are indicated in the treatment of infections caused by the following micro-organisms: mycoplasma pneumoniae: primary atypical pneumonia. rickettsiae: queensland tick typhus, typhus fever and q fever. agents of psittacosis. calymmatobacterium (donovania) granulomitis: granuloma inguinale. agents of lymphogranuloma venereum. borreliae: relapsing fever. chlamydia trachomatis. mayne pharma doxycycline capsules are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline capsules alone, or in combination with topical agents. mayne pharma doxycycline is indicated in the treatment of infections caused by the following gram-negative micro-organisms: vibrio species: cholera. brucella species: brucellosis (in conjunction with streptomycin). yersinia pestis: plague. francisella tularensis: tularemia. bartonella bacilliformis: bartonellosis. bacteroides species. when penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: treponema pallidum: syphilis. treponema pertenue: yaws. neisseria gonorrhoea: gonorrhoea (see dosage and administration). mayne pharma doxycycline capsules is not the drug of choice in the treatment of any type of staphylococcal infection or infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, streptococcus faecalis, or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxycycline should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory tract infections due to group a beta-haemolytic streptococci (including prophylaxis of rheumatic fever) penicillin is the usual drug of choice. doxycycline is active against both pre-erythroycitic and asexual bloodstages of plasmodium falciparum. the tetracyclines are only partially active against the pre-erythrocytic stages of plasmodium vivax and protection depends on drug suppression of the blood stages. doxycycline has no activity against the relapsing forms (hypnozoites) of plasmodium vivax. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by p. vivax. as there are relatively few locations where p. vivax does not co-exist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine. in acute intestinal amoebiasis mayne pharma doxycycline capsules may be a useful adjunct to amoebicides. in severe acne mayne pharma doxycycline capsules may be a useful adjunctive therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - doxycycline hyclate, quantity: 58.15 mg (equivalent: doxycycline, qty 50 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; hypromellose phthalate; hypromellose; hyprolose; povidone; wheat starch; diethyl phthalate; purified water; gelatin; ethanol; shellac; pharmaceutical glaze; carbon black - doxycycline is primarily bacteriostatic and is thought to exert its antimicrobial effect by the inhibition of protein synthesis. doxycycline is active against a wide range of gram-positive and gram-negative organisms. note: the 50 mg capsule is not a paediatric formulation. mayne pharma doxycycline capsules are indicated in the treatment of infections caused by the following micro-organisms: mycoplasma pneumoniae: primary atypical pneumonia. rickettsiae: queensland tick typhus, typhus fever and q fever. agents of psittacosis. calymmatobacterium (donovania) granulomitis: granuloma inguinale. agents of lymphogranuloma venereum. borreliae: relapsing fever. chlamydia trachomatis. mayne pharma doxycycline capsules are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline capsules alone, or in combination with topical agents. mayne pharma doxycycline is indicated in the treatment of infections caused by the following gram-negative micro-organisms: vibrio species: cholera. brucella species: brucellosis (in conjunction with streptomycin). yersinia pestis: plague. francisella tularensis: tularemia. bartonella bacilliformis: bartonellosis. bacteroides species. when penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: treponema pallidum: syphilis. treponema pertenue: yaws. neisseria gonorrhoea: gonorrhoea (see dosage and administration). mayne pharma doxycycline capsules is not the drug of choice in the treatment of any type of staphylococcal infection or infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, streptococcus faecalis, or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxycycline should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory tract infections due to group a beta-haemolytic streptococci (including prophylaxis of rheumatic fever) penicillin is the usual drug of choice. doxycycline is active against both pre-erythroycitic and asexual bloodstages of plasmodium falciparum. the tetracyclines are only partially active against the pre-erythrocytic stages of plasmodium vivax and protection depends on drug suppression of the blood stages. doxycycline has no activity against the relapsing forms (hypnozoites) of plasmodium vivax. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by p. vivax. as there are relatively few locations where p. vivax does not co-exist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine. in acute intestinal amoebiasis manye pharma doxycycline capsules may be a useful adjunct to amoebicides. in severe acne mayne pharma doxycycline capsules may be a useful adjunctive therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - minocycline hydrochloride dihydrate, quantity: 54 mg (equivalent: minocycline, qty 50 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; povidone; microcrystalline cellulose; sodium starch glycollate; sodium lauryl sulfate; titanium dioxide; hypromellose; indigo carmine; sunset yellow fcf; quinoline yellow; macrogol 400 - infections due to the following organisms, provided that they have been shown by bacteriological testing to be susceptible to minocycline: escherichia coli; enterobacter aerogenes; haemophilus influenzae; klebsiella and proteus. in addition, infections due to streptococcus pyogenes (group a beta-haemolytic) and streptococcus faecalis, however, because a large proportion of these organisms are resistant to tetracyclines, minocycline should be used only if the organisms have definitely been shown to be sensitive. tetracyclines, including minocycline, are not the drugs of choice in the treatment of staphylococcal infections. minocycline may be considered for the treatment of such infections only if other suitable agents are not available and the organism has been shown to be sensitive to minocycline. minocycline may be used in the treatment of tetracycline resistant acne.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - powder for suspension - amoxicillin as trihydrate 600 mg / 5 ml; clavulanic acid as potassium salt 42.9 mg / 5 ml - amoxicillin and enzyme inhibitor - augmentin es is indicated for the treatment of acute otitis media in children aged at least 3 months and less than 40 kg body weight, caused or thought likely to be caused by penicillin-resistant streptococcus pneumoniae:consideration should be given to official guidance on the appropriate use of antibacterial agents.

Philippines - English - FDA (Food And Drug Administration)

virbac philippines inc.; distributor: virbac philippines inc. - inactivated bordetella bronchiseptica , pasteurella multocida , actinobacillus pleuropneumoniae , mycoplasma hyopneumoniae , streptococcus suis , haemophilus parasuis vaccine (vet.) - suspension for injection (im) - formulation: each 1 ml (dose) contains: bordetella bronchiseptica -1 od bordetella bronchiseptica (dnt)-200 ug/ml pasteurella multocida (type a and d)-i od p. multocida type a (omp)-30 ug/ml actinobacillus pleuropneumoniae (serotype 2 and 5)-1 od p. multocida type d (dnt)-200 ug/ml mycoplasma hvopneumoniae-0.12 od a. pleuropneumoniae serotype 2 and 5 (toxin) 10 ug/ml streptococcus suis (type 2)-0.45 od haemophilus parasuis (serotype 1, 4 and 5)-0.45 od od - optical density at 410 nm absorbance (elisa) dnt – dermonecrotic toxin omp - outer membrane protein

Philippines - English - FDA (Food And Drug Administration)

virbac philippines inc.; distributor: virbac philippines inc. - inactivated streptococcus agalactiae fish vaccine (vet.) - emulsion for injection (ip) - formulation: each 0.1 ml (dose) contains: streptococcus agalactiae scrotype lb (ti098 strain) ≥ 1.8 x 108 cfu cfu - colony forming unit

Philippines - English - FDA (Food And Drug Administration)

virbac philippines inc.; distributor: virbac philippines inc. - inactivated streptococcus agalactiae ser. ia, ib, iii fish vaccine (vet.) - emulsion for injection (ip) - each 0.1 ml (dose) contains: streptococcus agalactiae serotype ib (t1098 strain)≥ 1.8 x 108 cfu streptococcus agalactiae serotype ia (ti191 strain)≥ 1.8 x 108 cfu streptococcus agalactiae serotype iii (ti198 strain) ≥ 1.8 x 108 cfu cfu - colony forming unit

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - enterococcus faecalis (unii: 15e04lz9ct) (enterococcus faecalis - unii:15e04lz9ct), streptococcus pneumoniae (unii: bt6u234yr2) (streptococcus pneumoniae - unii:bt6u234yr2), streptococcus viridans group (unii: nnv2379hkr) (streptococcus viridans group - unii:nnv2379hkr), streptococcus mutans (unii: 5c7j33mjj1) (streptococcus mutans - unii:5c7j33mjj1) - enterococcus faecalis 15 [hp_x] in 1 ml - for temporary relief of symptoms of strep infections.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms of strep infections.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - enterococcus faecalis (unii: 15e04lz9ct) (enterococcus faecalis - unii:15e04lz9ct), streptococcus pneumoniae (unii: bt6u234yr2) (streptococcus pneumoniae - unii:bt6u234yr2), streptococcus viridans group (unii: nnv2379hkr) (streptococcus viridans group - unii:nnv2379hkr), streptococcus mutans (unii: 5c7j33mjj1) (streptococcus mutans - unii:5c7j33mjj1) - enterococcus faecalis 15 [hp_x] in 1 ml - for temporary relief of symptoms related to sore throat such as swollen glands, pain and discomfort.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to sore throat such as swollen glands, pain and discomfort.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.